Yield10 Bioscience (NASDAQ:YTEN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Share on StockTwits

Yield10 Bioscience (NASDAQ:YTEN) announced its quarterly earnings data on Monday. The specialty chemicals company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.06, Bloomberg Earnings reports. Yield10 Bioscience had a negative return on equity of 126.91% and a negative net margin of 1,474.19%. The firm had revenue of $0.32 million during the quarter.

Shares of YTEN stock opened at $1.08 on Tuesday. The firm’s 50 day moving average is $0.92. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.49 and a current ratio of 4.49. The stock has a market capitalization of $11.99 million, a PE ratio of -1.17 and a beta of 3.21. Yield10 Bioscience has a twelve month low of $0.68 and a twelve month high of $1.77.

An institutional investor recently raised its position in Yield10 Bioscience stock. Renaissance Technologies LLC raised its holdings in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 478,176 shares of the specialty chemicals company’s stock after purchasing an additional 41,500 shares during the period. Renaissance Technologies LLC owned about 3.83% of Yield10 Bioscience worth $463,000 at the end of the most recent quarter. 7.43% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages recently weighed in on YTEN. Maxim Group reiterated a “buy” rating and set a $3.00 price target on shares of Yield10 Bioscience in a research report on Friday, May 31st. Aegis began coverage on Yield10 Bioscience in a research report on Monday, July 22nd. They set a “buy” rating for the company. National Securities reiterated a “buy” rating and set a $5.00 price target on shares of Yield10 Bioscience in a research report on Tuesday. Finally, Zacks Investment Research upgraded Yield10 Bioscience from a “sell” rating to a “hold” rating in a research report on Sunday, July 14th.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

See Also: Does a trade war provide a risk to the global economy?

Earnings History for Yield10 Bioscience (NASDAQ:YTEN)

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

State Board of Administration of Florida Retirement System Lowers Stock Holdings in Torchmark Co.
State Board of Administration of Florida Retirement System Lowers Stock Holdings in Torchmark Co.
Securian Asset Management Inc Grows Stock Position in Viacom, Inc.
Securian Asset Management Inc Grows Stock Position in Viacom, Inc.
Zacks: Analysts Expect Santander Consumer USA Holdings Inc  to Post $0.67 Earnings Per Share
Zacks: Analysts Expect Santander Consumer USA Holdings Inc to Post $0.67 Earnings Per Share
Dynavax Technologies Co.  Receives Average Rating of “Buy” from Analysts
Dynavax Technologies Co. Receives Average Rating of “Buy” from Analysts
Cara Therapeutics Inc  Expected to Announce Earnings of -$0.59 Per Share
Cara Therapeutics Inc Expected to Announce Earnings of -$0.59 Per Share
Essential Properties Realty Trust Inc  Receives Consensus Recommendation of “Hold” from Analysts
Essential Properties Realty Trust Inc Receives Consensus Recommendation of “Hold” from Analysts


© 2006-2019 Ticker Report